BIOREN (Predictive BIOmarkers in Metastatic RENal Cancer) (BIOREN)
BIOREN (Predictive BIOmarkers in Metastatic RENal Cancer) - A Translational Study on Immunotherapy for Metastatic Renal Cancer
Sponsor: Centre Leon Berard
Listed as NCT03628859, this observational or N/A phase trial focuses on Renal Cancer Metastatic and remains ongoing. Sponsored by Centre Leon Berard, it has been updated 11 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Apr 2024 — Jul 2024 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
-
Apr 2022 — Apr 2024 [monthly]
Recruiting
-
Dec 2021 — Apr 2022 [monthly]
Recruiting
▶ Show 6 earlier versions
-
Mar 2021 — Dec 2021 [monthly]
Recruiting
-
Jan 2021 — Mar 2021 [monthly]
Recruiting
-
Nov 2020 — Jan 2021 [monthly]
Recruiting
-
Jul 2020 — Nov 2020 [monthly]
Recruiting
-
Feb 2019 — Jul 2020 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Sep 2018 — Feb 2019 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Centre Leon Berard
For direct contact, visit the study record on ClinicalTrials.gov .